Stimcell Energetics (STME) FCF Margin (2016 - 2023)
Stimcell Energetics' (STME) quarterly FCF Margin came in at 34627.03% in Q2 2023, down 2665921.0% year-on-year from N/an in Q2 2022, and up 25.63% quarter-over-quarter from 46560.36% in Q1 2023.
Stimcell Energetics (STME) FCF Margin (2016 - 2023) Analysis & Trends
Stimcell Energetics' FCF Margin history runs 7 years deep, the most recent figure standing at 34627.03% for Q2 2023.
- On a quarterly basis, FCF Margin fell 2665921.0% year-over-year to 34627.03% in Q2 2023; TTM through Feb 2024 was 188181.08%, a 17571623.0% decrease from a year earlier, with the FY2023 full-year figure at 9855.5%, up 902137.0% from the prior year.
- FCF Margin improved to 34627.03% in Q2 2023 per STME's latest filing, from 46560.36% in the prior quarter.
- Across five years, FCF Margin topped out at 302.46% in Q2 2020 and bottomed at 46560.36% in Q1 2023.
- The 5-year median for FCF Margin is 8698.87% (2020), against an average of 12552.33%.
- Across the five-year window, FCF Margin soared 434793 bps in 2021 and slumped 2665921 bps in 2023, its largest moves.
- Year by year, FCF Margin stood at 2693.05% in 2019, then sank by 186 bps to 7704.12% in 2020, then rose by 9 bps to 6997.25% in 2021, then dropped by 19 bps to 8320.94% in 2022, then plunged by 316 bps to 34627.03% in 2023.
- Per Business Quant, the three latest STME FCF Margin figures stand at 34627.03% (Q2 2023), 46560.36% (Q1 2023), and 8320.94% (Q4 2022).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Stimcell Energetics | 5.85 Mn | 5.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2023 | -34,627.03% |
| Feb 28, 2023 | -46,560.36% |
| Nov 30, 2022 | -8,320.94% |
| Aug 31, 2022 | -14,661.82% |
| May 31, 2022 | -7,967.82% |
| Feb 28, 2022 | -20,797.16% |
| Nov 30, 2021 | -6,997.25% |
| Aug 31, 2021 | -12,642.02% |
| May 31, 2021 | -11,071.86% |
| Feb 28, 2021 | -4,728.88% |
| Nov 30, 2020 | -7,704.12% |
| Aug 31, 2020 | -11,670.28% |
| May 31, 2020 | -302.46% |
| Feb 29, 2020 | -9,076.81% |
| Nov 30, 2019 | -2,693.05% |
| Aug 31, 2019 | -1,015.44% |
| Feb 28, 2017 | -48,860.27% |
| Nov 30, 2016 | -83,339.58% |
| Aug 31, 2016 | -2,574.96% |
| May 31, 2016 | -950.51% |